Induced Pluripotent Stem Cells Production Market To Reach $3.78 Billion By 2033

Induced Pluripotent Stem Cells Production Market Growth & Trends

The global induced pluripotent stem cells production market size is expected to reach USD 3.78 billion by 2033, registering a CAGR of 10.01% from 2025 to 2033, according to a new report by Grand View Research, Inc. The increase in demand for induced pluripotent stem cells (iPSCs) in comparison to Embryonic Stem Cells (ESCs) has offered a significant drive to the market. Advantages such as no stem cell-related ethical issues, personalized treatment, and flexibility during cell-based research have created a favorable scenario for market growth. In addition, the prevalence of chronic disorders is also driving the growth of the induced pluripotent stem cells production market, as conditions like heart disease, stroke, diabetes, and many more can be treated by utilizing iPSCs-mediated therapy. For example, according to the International Diabetes Federation (IDF), 537 million people are already living with diabetes in 2021.

The rising research activities during COVID-19 pandemic have positively impacted the market. The pandemic fueled research in many fields as the SARS CoV-2 infection resulted in many diseases in the patients. For instance, in April 2021, researchers from USA stated that up to 25% of COVID-19 patients suffered cardiac dysfunction. Through their research article, they demonstrated the pathogenesis via exposure of iPSCs-derived cardiac cells to SARS CoV-2, and similar alterations were confirmed from human autopsy specimens of the patients. Such insights allow the use of induced pluripotent stem cells (iPSCs) as drug or therapy development platforms and their utilization in the management of the long-term effects of COVID-19.

Induced pluripotent stem cells are cells that are derived from adult somatic cells and then further reprogrammed to obtain the pluripotency as that of ESCs. These iPSCs are proving to be an ethically uncomplicated alternative for research that involves ESCs. The derivation of the ESCs is associated with the destruction of an embryo at the blastocyte stage, which has led to a maximum number of ethical debates. However, induced pluripotent stem cells have solved the ethical issue over the destruction of human embryos in research by involving only the genetic reprogramming of somatic cells. This has propelled the market growth and resulted in numerous applications including drug discovery, disease modeling, toxicology testing, and many others. For instance, in August 2021, Fate Therapeutics announced the treatment of the first patient with FT819 during clinical trials. FT819 is an engineered CAR-T cell therapy that is derived from iPSCs. Also, the rising focus of the research community on exploring applications of induced pluripotent stem cells in regenerative medicine due to their unique characteristics such as differential potential, self-renewable, immunomodulatory properties, and others; is set to drive the market expansion.

 Request a free sample copy or view the report summary: Induced Pluripotent Stem Cells Production Market Report

Induced Pluripotent Stem Cells Production Market Report Highlights

• The manual iPSC production process segment dominated the induced pluripotent stem cells production market and accounted for the largest revenue share in 2024.

• The cell culture segment dominated the market with the largest revenue share of 37.26% in 2024. Cell culture workflow includes revenues generated from iPSC harvest products, expansion products, and differentiation products, thus contributing to the market relevance of this segment.

• The consumables and kits segment dominated the induced pluripotent stem cells production industry with the largest revenue share of 39.97% in 2024.

• The drug development & discovery segment accounted for the largest revenue share of 43.26% in 2024, driven by the increasing use of iPSC-derived cell models for advanced screening, disease modeling, and toxicity testing, which offer superior physiological relevance and predictive accuracy compared to conventional immortalized cell lines or animal models.

• The biotechnology & pharmaceutical companies segment dominated the induced pluripotent stem cells production market with the largest revenue share of 59.41% in 2024.

• North America led the induced pluripotent stem cells production market with the largest revenue share of 40.66% in 2024.

Induced Pluripotent Stem Cells Production Market Segmentation

Grand View Research has segmented the global induced pluripotent stem cells production market on the basis of process, workflow, product, application, end use, and region:

Induced Pluripotent Stem Cells Production Process Outlook (Revenue, USD Million, 2021 - 2033)

• Manual iPSC Production Process

• Automated iPSC Production Process

Induced Pluripotent Stem Cells Production Workflow Outlook (Revenue, USD Million, 2021 - 2033)

• Reprogramming

• Cell Culture

• Cell Characterization/Analysis

• Engineering

• Others

Induced Pluripotent Stem Cells Production Product Outlook (Revenue, USD Million, 2021 - 2033)

• Instruments/ Devices

• Automated Platforms

• Consumables & Kits

  • Media

  • Kits

  • Others

• Services

Induced Pluripotent Stem Cells Production Application Outlook (Revenue, USD Million, 2021 - 2033)

• Drug Development & Discovery

• Regenerative Medicine

• Toxicology Studies

• Others

Induced Pluripotent Stem Cells Production End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Research & Academic Institutes

• Biotechnology & Pharmaceutical Companies

• Hospitals & Clinics

Induced Pluripotent Stem Cells Production Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Induced Pluripotent Stem Cells Production Market

• Lonza

• Axol Bioscience Ltd.

• Evotec

• Hitachi, Ltd.

• REPROCELL Inc.

• Merck KGaA

• Fate Therapeutics

• Thermo Fisher Scientific, Inc.

• StemCellsFactory III

• Applied StemCells, Inc.